Bicara Therapeutics Statistics
Total Valuation
BCAX has a market cap or net worth of $1.77 billion. The enterprise value is $1.23 billion.
Important Dates
The next estimated earnings date is Tuesday, August 11, 2026, before market open.
| Earnings Date | Aug 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BCAX has 65.70 million shares outstanding. The number of shares has increased by 85.90% in one year.
| Current Share Class | 65.70M |
| Shares Outstanding | 65.70M |
| Shares Change (YoY) | +85.90% |
| Shares Change (QoQ) | +10.11% |
| Owned by Insiders (%) | 1.89% |
| Owned by Institutions (%) | 72.81% |
| Float | 36.65M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 3.43 |
| P/TBV Ratio | 3.44 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 13.85, with a Debt / Equity ratio of 0.00.
| Current Ratio | 13.85 |
| Quick Ratio | 13.72 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -32.34% and return on invested capital (ROIC) is -22.32%.
| Return on Equity (ROE) | -32.34% |
| Return on Assets (ROA) | -21.09% |
| Return on Invested Capital (ROIC) | -22.32% |
| Return on Capital Employed (ROCE) | -33.85% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.53M |
| Employee Count | 103 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, BCAX has paid $197,000 in taxes.
| Income Tax | 197,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +200.56% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +200.56% |
| 50-Day Moving Average | 22.14 |
| 200-Day Moving Average | 18.21 |
| Relative Strength Index (RSI) | 78.04 |
| Average Volume (20 Days) | 858,370 |
Short Selling Information
The latest short interest is 10.08 million, so 15.35% of the outstanding shares have been sold short.
| Short Interest | 10.08M |
| Short Previous Month | 9.85M |
| Short % of Shares Out | 15.35% |
| Short % of Float | 27.51% |
| Short Ratio (days to cover) | 19.69 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -174.06M |
| Pretax Income | -157.12M |
| Net Income | -157.32M |
| EBITDA | -173.93M |
| EBIT | -174.06M |
| Earnings Per Share (EPS) | -$2.80 |
Full Income StatementBalance Sheet
The company has $539.75 million in cash and $1.44 million in debt, giving a net cash position of $538.31 million or $8.19 per share.
| Cash & Cash Equivalents | 539.75M |
| Total Debt | 1.44M |
| Net Cash | 538.31M |
| Net Cash Per Share | $8.19 |
| Equity (Book Value) | 513.96M |
| Book Value Per Share | 7.84 |
| Working Capital | 505.58M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$116.24 million and capital expenditures -$340,000, giving a free cash flow of -$116.58 million.
| Operating Cash Flow | -116.24M |
| Capital Expenditures | -340,000 |
| Depreciation & Amortization | 130,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -116.58M |
| FCF Per Share | -$1.77 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |